Since extended treatment with the HER2 inhibitors results in the suppression of HER2 expression, we questioned whether prolonged treatment with an HER2 inhibitor lapatinib sensitizes HER2+ breast cancer lines to combined TAM/Met and CDK4/6 inhibition. The gene discussed is CDK4; the disease is breast carcinoma.